SIGMA HEALTHCARE LIMITED (SIG)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

SIG

SIG - SIGMA HEALTHCARE LIMITED

FNArena Sector : Health & Nutrition
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: -3.13
Index: ASX100 | ASX200 | ASX300 | ALL-ORDS

LAST PRICE CHANGE +/- CHANGE % VOLUME

$3.03

20 May
2025

0.100

OPEN

$2.97

3.41%

HIGH

$3.06

37,342,090

LOW

$2.94

TARGET
$2.956 -2.4% downside
Franking for last dividend paid out: 50%
OTHER COMPANIES IN THE SAME SECTOR
CLV . EBO . EXL . MCP .
FNARENA'S MARKET CONSENSUS FORECASTS
SIG: 1
Title FY23
Actual
FY24
Actual
FY25
Forecast
FY26
Forecast
EPS (cps) xxx 0.4 4.0 xxx
DPS (cps) xxx 1.0 1.3 xxx
EPS Growth xxx 100.0% 100.0% xxx
DPS Growth xxx 1.5% 34.5% xxx
PE Ratio xxx N/A 76.0 xxx
Dividend Yield xxx N/A 0.4% xxx
Div Pay Ratio(%) xxx 223.9% 32.8% xxx

Dividend yield today if purchased 3 years ago: 1.97%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

0.32

Estimated Dividend Growth
(Average Of Past Three Years)

 %

Amount Invested

Tell Me The Dividend After This Many Years

Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 28/03 - ex-div 0.5c (franking 50%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 202020212022202320242025
EPS Basic xxxxxxxxxxxxxxx-0.9
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx4,841.2 M
Book Value Per Share xxxxxxxxxxxxxxx53.2
Net Operating Cash Flow xxxxxxxxxxxxxxx-315.6 M
Net Profit Margin xxxxxxxxxxxxxxx-0.29 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202020212022202320242025
Return on Capital Employed xxxxxxxxxxxxxxx-1.62 %
Return on Invested Capital xxxxxxxxxxxxxxx-1.41 %
Return on Assets xxxxxxxxxxxxxxx-0.85 %
Return on Equity xxxxxxxxxxxxxxx-1.62 %
Return on Total Capital xxxxxxxxxxxxxxx-5.79 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-339.3 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202020212022202320242025
Short-Term Debt xxxxxxxxxxxxxxx11 M
Long Term Debt xxxxxxxxxxxxxxx121 M
Total Debt xxxxxxxxxxxxxxx132 M
Goodwill - Gross xxxxxxxxxxxxxxx89 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx15 M
Price To Book Value xxxxxxxxxxxxxxx5.39

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202020212022202320242025
Capex xxxxxxxxxxxxxxx7.9 M
Capex % of Sales xxxxxxxxxxxxxxx0.16 %
Cost of Goods Sold xxxxxxxxxxxxxxx4,586 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx313 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx9 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.2

No. Of Recommendations

5
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Citi

xx/xx/xxxx

3

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgan Stanley

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Ord Minnett

26/03/2025

3

Hold

$2.73

-9.90%

Ord Minnett's previous update on Sigma Healthcare dates from before the financial results release in March, at least on our observation.

This might explain why today's health sector update lists the broker's price target as $2.73 versus $2.15 back then. Hold.

FORECAST
Ord Minnett forecasts a full year FY25 dividend of 1.00 cents and EPS of 2.40 cents.
Ord Minnett forecasts a full year FY26 dividend of 3.80 cents and EPS of 5.40 cents.

Macquarie

xx/xx/xxxx

5

xxxxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgans

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Goldman Sachs

12/05/2025

3

Neutral

$2.70

-10.89%

Following an update from Sigma Healthcare after the completion of the merger with Chemist Warehouse, Goldman Sachs left the FY25 normalised EBIT forecast unchanged at $811m. FY26-27 forecasts are unchanged too.

The broker believes the update showed 3Q25 sales growth in Chemist Warehouse were strong and largely consistent with the 1H25 growth rate.

The broker assumes a limited transaction cost impact for the rest of FY25. Neutral. Target unchanged at $2.70.

FORECAST
Goldman Sachs forecasts a full year FY25 dividend of 0.00 cents and EPS of 5.00 cents.
Goldman Sachs forecasts a full year FY26 dividend of 4.00 cents and EPS of 5.00 cents.

SIG STOCK CHART